How the histamine N-methyltransferase inhibitor metoprine alleviates methamphetamine reward
<p>Methamphetamine (METH) is a highly addictive psychomotor stimulant drug that is abused worldwide [1].<br>METH abuse results in numerous adverse effects after acute administration, as well as an array of adverse outcomes associated with binge use, long-term use, and withdrawal [2- 4]....
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Journal of Addiction Medicine and Therapeutic Science - Peertechz Publications,
2017-05-12.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <p>Methamphetamine (METH) is a highly addictive psychomotor stimulant drug that is abused worldwide [1].<br>METH abuse results in numerous adverse effects after acute administration, as well as an array of adverse outcomes associated with binge use, long-term use, and withdrawal [2- 4]. Acutely METH releases dopamine from synaptic terminals through multiple actions that include inducing reverse transport of dopamine via the dopamine transporter (DAT), impairing the function of the vesicular monoamine transporter-2 (VMAT2), leading to increased cytoplasmic dopamine concentrations,<br>and inhibition of monoamine oxidase [5-8]. Moreover, these changes contribute to the production of oxidative metabolites, metabolic impairments, oxidative damage to dopamine terminals, and depletion of tissue dopamine levels [9-11]. METH and related drugs consequently produce broad effects on the central nervous system both acutely and chronically [12-14].<br></p> |
|---|---|
| DOI: | 10.17352/2455-3484.000021 |